Eleonora Lad, MD, PhD and Ramin Tadayoni, MD, PhD
Show Description +
What are the latest data from the phase 3 DERBY and OAKS studies assessing the safety and efficacy of pegcetacoplan (Syfovre, Apellis Pharmaceuticals) for the treatment of geographic atrophy? And how can clinicians use these data to inform their decision-making now that the drug is approved in the United States? Eleonora Lad, MD, PhD, joins Clinical Minute: Retina host Ramin Tadayoni, MD, PhD, for a discussion about the newest data on functional outcomes. They review which workflow adjustments Dr. Lad has implemented to accommodate increased patient volume, and consider how European clinicians can best learn from their American colleagues’ early experiences with this newly approved therapy.
Posted: 5/12/2023
Eleonora Lad, MD, PhD and Ramin Tadayoni, MD, PhD
What are the latest data from the phase 3 DERBY and OAKS studies assessing the safety and efficacy of pegcetacoplan (Syfovre, Apellis Pharmaceuticals) for the treatment of geographic atrophy? And how can clinicians use these data to inform their decision-making now that the drug is approved in the United States? Eleonora Lad, MD, PhD, joins Clinical Minute: Retina host Ramin Tadayoni, MD, PhD, for a discussion about the newest data on functional outcomes. They review which workflow adjustments Dr. Lad has implemented to accommodate increased patient volume, and consider how European clinicians can best learn from their American colleagues’ early experiences with this newly approved therapy.
Posted: 5/12/2023
Please log in to leave a comment.